

SANOFI'S COMMITMENT AND CONTRIBUTION TO THE UN SUSTAINABLE DEVELOPMENT GOALS

Health plays a decisive role in fostering economic growth and sustainable development. Because of its indirect impact on human development, better health boosts rates of economic growth and contributes to wealth creation. During the period 2000-2015, Sanofi was involved in addressing the health challenges set out in the United Nations Millennium Development Goals (MDGs) in an effort to reduce poverty and advance human development—for instance, by decreasing infant mortality rates, improving maternal health, fighting infectious diseases like malaria, investing in Research & Development and creating global partnerships for development.

Sanofi supports the more ambitious health objectives of the new Sustainable Development Goals (SDGs) covering 2016-2030, which replace the MDGs. As a healthcare company, we are committed to scaling up our engagement to achieve health-related goals, such as those concerning infectious and non-communicable diseases and universal health coverage. We are ready to provide our support through the development of new medicines and vaccines, but also through innovative partnerships in a wide range of areas: R&D, training for healthcare professionals, integrated access schemes for patients and disease management programs, etc.

During the United Nations Private Sector Forum 2015, of the 35 business commitments selected to achieve the new SDGs, two were proposed by Sanofi: our Sanofi Espoir Foundation's program "My Child Matters" which aims to fight childhood cancer in low- and middle-income countries in partnership with St. Jude Children's Research Hospital, the International Society of Pediatric Oncology (SIOP), the Union for International Cancer Control (UICC), the French-African Pediatric Oncology Group (GFAOP) and Childhood Cancer International (CCI) and the joint price support mechanism announced by Sanofi Pasteur and the Bill and Melinda Gates Foundation making it possible for us to provide inactivated poliovirus vaccine (IPV) to 73 of the world's poorest countries in order to help reach the goal of polio eradication by 2018.

Our involvement at the highest level of the company in the Access Accelerated Initiative (AAI)¹ is a way to upgrade our contribution to the SDGs in the fields of non-communicable diseases (NCDs). Through the AAI, Sanofi and other pharmaceutical companies pledge to commit to helping achieve the United Nations Sustainable Development Goals, and in particular, to reduce premature deaths from NCDs by one-third by 2030. During the launch of the initiative in January 2017 at the Davos Summit, Sanofi committed to contributing in the fields of diabetes, mental health and child cancer. (see SDG Goal 17 below in this document)

Sanofi has been running many other activities that can contribute to the realization of the SDGs.² The list presented below is not exhaustive. Other programs in the field of access to healthcare, environment policy, etc., aiming at addressing the SDGs' Goals can be found in our download center: http://en.sanofi.com/csr/download_center/download_center.aspx

¹ <http://www.accessaccelerated.org/>

² The categorization of our actions described follows the draft SDG Industry Matrix Healthcare & Life Sciences produced jointly by the United Nations Global Compact and KPMG International. https://www.unglobalcompact.org/docs/issues_doc/development/SDGMatrix-Healthcare.pdf

SDG GOAL 1 – NO POVERTY

End poverty in all its forms everywhere



ZINA health project in Madagascar
Partners since 2001, Sanofi and the NGO Positive Planet are committed to developing innovative solutions to help provide access to healthcare for disadvantaged populations, particularly in Madagascar, through the creation of micro-insurance systems. In Madagascar, a majority of the population, rural and urban, lives in conditions where access to healthcare is difficult. To promote access to affordable quality care, the ZINA project has set up micro-insurance initiatives in the three Madagascar regions that benefit from a common technical platform. To date, ZINA has supported nearly 20,000 beneficiaries.
Partners: Positive Planet
Links/sources: http://en.sanofi.com/csr/news/2015-01-23_plaNet_finance.aspx
Other SDG Goals addressed: SDG Goal 3 – Good Health and Well-Being, SDG Goal 10 – Reduced Inequalities

Sanofi Espoir Foundation: Programs for emergency situations
Humanitarian crises are unpredictable and often have tragic consequences, which mean they require a fast, efficient and generous response from the international community. As a healthcare partner, the Sanofi Espoir Foundation is able to 'scramble' immediately. It works with the emergency's partners and local Sanofi subsidiaries to coordinate actions that will provide the victims with rapid access to care. Depending on the needs it identifies, it can ship drugs and vaccines under a charter based on World Health Organization (WHO) guidelines, as well as send financial donations to local stakeholders to enable them to deploy emergency and post-emergency operations.
Since the Sanofi Espoir Foundation was created in 2010, we have provided support within the framework of humanitarian emergencies to over 14 million injured, disaster-stricken or displaced people in 75 countries.
In 2016, the Sanofi Espoir Foundation donated 122,204 boxes of medicines and 331,500 doses of vaccines to benefit an estimated 857,000 people in six countries (China, Ecuador, Haiti, India, Japan and Macedonia).
Partners: Tulip (emergency and international solidarity association)
Links/sources: http://fondation-sanofi-espoir.com/en/humanitarian_emergencies.php
Other SDG Goals addressed: SDG 11 – Sustainable cities and communities

SDG GOAL 2 – ZERO HUNGER

End hunger, achieve food security and improve nutrition and promote sustainable agriculture



Kids and Diabetes in Schools (KiDS)

The number of children with Type 1 and Type 2 diabetes is increasing worldwide. To date, it is estimated that 542,000 children have Type 1 diabetes. Sanofi launched the “Kids and Diabetes in Schools” (KiDS) program in India in 2013 and Brazil in 2014 in collaboration with the International Diabetes Federation, the International Society for Pediatric and Adolescent Diabetes and its local partners. KiDS aims to foster a safe and supportive school environment that creates a better understanding of diabetes and supports children with this condition. It also provides information about how suitable lifestyle choices can help prevent Type 2 diabetes. To date, KiDS has reached around 4,800 teachers and 45,000 students. In India and Brazil, the KiDS results report an overall improvement in meal quality and access to healthy food choices, with also some schools taking some steps to prohibit the consumption of junk food. There was also an increased focus on physical activity in both countries, including the introduction of yoga classes in some schools in India. In 2016, KiDS was launched in two additional countries: Pakistan and the United Arab Emirates. KiDS is one of the Sanofi initiatives included in the Access Accelerated Initiative aiming to fight non-communicable diseases, which was presented at the Davos Summit in January 2017. Sanofi is involved in similar awareness and education programs in schools in Turkey, Canada and Algeria.

Partners: International Diabetes Federation (IDF), International Society for Pediatric and Adolescent Diabetes (ISPAD), Public Health Foundation of India (PHFI), Health Related Information Dissemination Amongst Youth (HRIDAY), Brazilian Society of Diabetes (SBD), Brazilian Society of Pediatrics (SBP)

Links/sources:

<http://www.epresspack.net/sanofi-diabetes-global-health/kids-project-improves-school-environment-for-children-with-diabetes/>
<http://www.accessaccelerated.org/initiative/kids-and-diabetes-in-schools-kids/>

Other SDG Goals addressed: SDG Goal 3 – Good health and well-being

Developing the first-ever dengue vaccine and making it available

After 20 years of research and development, Sanofi Pasteur launched the first dengue vaccine. On December 9, 2015, Mexico was the first country to grant marketing authorization to Dengvaxia®, our tetravalent vaccine for the prevention of diseases caused by all four dengue virus serotypes in preadolescents, adolescents and adults (aged 9 to 45) living in endemic areas. Sanofi Pasteur enrolled over 40,000 participants in extensive safety and clinical efficacy studies and built a dedicated vaccine production facility in France to ensure that the quality and quantities of the vaccine will be sufficient to meet demand upon introduction. The marketing authorization of Dengvaxia® in Mexico was followed by approvals in the Philippines, Brazil in 2015 and El Salvador in 2016. As of December 1, 2016, Dengvaxia® had been approved in 13 countries (Bolivia, Brazil, Cambodia, Costa Rica, Guatemala, El Salvador, Indonesia, Mexico, Paraguay, Peru, the Philippines, Singapore, Thailand). We are introducing Dengvaxia® first in those countries where the vaccine has the greatest potential to reduce dengue burden globally and help to achieve the WHO’s goal to reduce dengue mortality by 50% and morbidity by 25% by 2020 in endemic countries. Public programs are underway in Brazil (for children, adolescents and adults in Parana State) and in the Philippines (through a school-based program). Regulatory review processes for Dengvaxia® continue in other endemic countries, and Sanofi Pasteur remains committed to introducing the vaccine first in countries where the disease is a major public health priority. In July 2016, the WHO issued its recommendation that countries with a high dengue burden consider vaccination to help better control the disease.³

³ WHO, Weekly Epidemiological Record, No 30, July 2016, 91, pp. 349 – 364: <http://www.who.int/wer/2016/wer9130.pdf?ua=1>

Partners: -
Links/sources: http://www.sanofipasteur.com/en/articles/dengvaxia-world-s-first-dengue-vaccine-approved-in-mexico.aspx http://www.sanofipasteur.com/en/articles/sanofi-pasteur-dengue-vaccine-approved-in-the-philippines.aspx http://www.sanofipasteur.com/en/articles/Dengvaxia-First-Dengue-Vaccine-Approved-in-Brazil.aspx http://www.sanofipasteur.com/en/Documents/PDF/PR-locaux/EI%20Salvadore%20LICENSE%20DENGVAXIA%20ENG_050216.pdf http://www.sanofipasteur.com/en/articles/World-s-First-Public-Dengue-Immunization-Program-Starts-in-the-Philippines.aspx http://www.sanofipasteur.com/en/articles/Dengue-Immunization-Public-Program-in-Parana-State-of-Brazil.aspx
Other SDG Goals addressed: SDG Goal 3 – Good health and well-being

SDG GOAL 3 – GOOD HEALTH AND WELL-BEING

Ensure healthy lives and promote well-being for all at all ages



Ghana Accessibility and Affordability Programme (GAAP)
<p>The GAAP Pilot Project is a public private initiative (involving Ghana authorities, the Bill & Melinda Gates Foundation, other pharma companies and other partners), which aims to provide access to effective, safe and affordable medicines for the treatment of non-communicable diseases (NCDs). The initiative is targeting underserved Ghanaians of low and middle-income socio-economic status suffering from NCDs such as diabetes, hypertension and cancer. MoU was signed with the Ministry of Health in October 2014. Patients who are eligible for treatment and accept to take part in the study are assigned to either the 'differentially-priced' or 'market-priced' group, based on their household or their score in the Multidimensional Poverty Index. The pilot is a unique opportunity to incorporate supplementary system strengthening efforts such as patient education and medical capacity building to address other barriers (i.e. training of all clinical staff, supply chain management training, hypertension and diabetes treatment guidelines, patient education) and medicine access interventions. Sanofi provides treatments for the three diseases (hypertension, diabetes and cancer). A similar pilot program is underway in the Philippines. When the studies are completed mid-2017, a team from Johns Hopkins University will measure the extent to which the approach is effective and sustainable. The companies will then decide whether to introduce differential pricing for NCD medicines on a wider scale in Ghana and the Philippines, and in other markets.</p>
<p>Partners: Bill and Melinda Gates Foundation, Ghana Ministry of Health, Ghana Health Service, National Health Insurance Authority, Food and Drugs Authority, MSD, Pfizer, UK Department for International Development, Johns Hopkins University, New Venture Fund</p>
<p>Links/sources: http://allafrica.com/stories/201402210982.html http://www.accessaccelerated.org/initiative/access-and-affordability-initiative/ </p>
<p>Other SDG Goals addressed: SDG Goal 1 – No Poverty; DSG Goal 10 – Reduced Inequalities</p>

AllStar™: A state-of-the-art insulin pen for patients in emerging markets

Our AllStar™ pen demonstrates our focus on innovation in diabetes and our commitment to help provide access to healthcare in emerging markets by taking a regionalized approach to finding solutions that are adapted to local market needs. To meet the needs of patients in emerging markets and improve access to innovative affordable devices, Sanofi India Limited launched in 2012 the first re-usable insulin pen manufactured by a global company in India. AllStar™ manufacturing requires state of the art and well controlled processes that were transferred by Sanofi through a collaborative approach to two local manufacturers based in India. AllStar™ is indicated for patients already using products in Sanofi's insulin portfolio as well as those who are starting to take insulin for the first time. It supports physicians in early initiation of insulin therapy for better glycemic control and enhanced therapeutic outcomes. Featuring a sleek design and easy-to-use yet sophisticated technology, it combines both convenience and affordability and conforms to the International Organization for Standardization (ISO) standards. Since its launch in India, AllStar™ has been marketed in several additional emerging countries such as Bangladesh, South Africa, Malaysia, Thailand, and Egypt.

Partners: Local manufacturers

Links/sources: http://en.sanofi.com/Images/31214_20121009_INDIAALLSTAR_en.pdf

Other SDG Goals addressed: SDG Goal 1 – No Poverty

Be He@lthy Be Mobile

Sanofi is a partner of “Be He@lthy, Be Mobile,” a ground-breaking initiative led by the International Telecommunication Union in collaboration with the WHO, public and private sector organizations, governments, the United Nations, industry and academia. This program uses technology to improve the prevention, treatment and care of non-communicable diseases in several priority countries. By increasing collaborations between different health Information and Communications Technology (ICT) and technology actors in the mobile ecosystem, one of the ambitions of this initiative is to enhance country capacities to strengthen health systems in order to assess the growing burden of non-communicable diseases. Mobile solutions for diabetes represent a unique opportunity to create a much-needed continuum of care, including prevention and support targeting different segments of the population. Sanofi is part of the “mDiabetes,” one of the 8 “mHealth” programs of this overall initiative, already started in Senegal. This includes targeted SMS messaging to general population, people living with diabetes and healthcare professionals through several campaigns during the year, and particularly during the month of Ramadan (known as “mRamadan”). In December 2015, on the occasion of the World Diabetes Congress were presented the first results of the 2nd mRamadan campaign. Over 10,000 individuals were reached through this campaign (an increase of around 65% compared to pilot year), and some behavioral nutritional changes were observed during this period of high sugar consumption and dietary irregularity where health authorities witness a peak in the urgent hospitalization of people with uncontrolled diabetes. Since the launch of the program, more than 430,000 SMS have been sent. This is a good illustration of the strengths of a multi-sector structure that brings together the expertise, knowledge and willingness to address a society-wide health issue. In 2016, the program was also launched in Egypt.

Partners: International Telecommunication Union (ITU), World Health Organization (WHO), public private sector organizations, governments, United Nations, industry, academia

Links/sources: <http://www.epresspack.net/sanofi-diabetes-global-health/sanofi-joins-itu-in-the-be-healthy-be-mobile-initiative-bringing-mobile-health-solutions-to-people-with-diabetes/>

Other SDG Goals addressed: SDG Goal 17 – Partnerships for the Goals

Diabetes and tuberculosis
<p>The co-existence of two epidemics, tuberculosis and diabetes, represents a serious public health challenge for health care systems, particularly in the low- and middle-income countries. The biological basis for the association between both diseases is not fully understood. However, the interplay between diabetes and tuberculosis is an infectious and deadly combination which presents a number of complexities not seen when the two diseases present in isolation. A person with diabetes has a two to three times greater risk of developing active tuberculosis. Diabetes is also a risk factor for tuberculosis treatment failure and death. An estimated 2.3 million adults in South Africa have diabetes and prevalence is on the rise. In November 2015, Sanofi announced a joint program with the University Research Co. along with the South African Aquity Innovations and the National Department of Health. The purpose of this project is to improve early detection of concomitant diabetes and tuberculosis, and support patient management. Targeting the provinces of KwaZulu Natal, Eastern Cape, Gauteng and Free State, this initiative will help bolster healthcare workers' skills and practices, integrate diabetes and tuberculosis care into routine health services, and teach patients about disease prevention and control. In 2016, training programs for healthcare professionals were developed and certified by the Health Professional Council of South Africa. A total of 535 healthcare professionals were trained (27 physicians, 214 nurses and 294 community health workers). Moreover, advocacy, communication and social mobilization activities contributed to awareness-raising for around 3,700 people.</p>
<p>Partners: University Research Co (URC), National Department of Health (South Africa)</p>
<p>Links/sources: http://www.epresspack.net/sanofi-diabetes-global-health/sanofi-south-africa-urc-and-ndoh-partner-to-improve-screening-diagnosis-and-management-in-diabetes-and-tuberculosis/</p>
<p>Other SDG Goals addressed: SDG Goal 1 – No Poverty</p>

Innovating to provide access to affordable and quality anti-malarial treatments
<p>Sanofi takes a comprehensive approach to the fight against malaria through initiatives designed to prevent, diagnose, treat and inform. In particular, we are committed to finding sustainable solutions to provide medicines at preferential prices to patients in need according to applicable law.</p> <p>ArteSunate AmodiaQuine Winthrop® (ASAQ Winthrop®) was developed through an innovative partnership with Drugs for Neglected Diseases <i>initiative</i> (DNDi), an independent non-profit foundation. It is the first anti-malarial drug to come out of a public-private partnership. This combined, fixed-dose formulation enables better adherence to treatment and reduces the risk of drug resistance. ASAQ Winthrop® is available at a price of less than US\$1 for adults and US\$0.50 for children, for a full three-day treatment regimen. Sanofi did not seek patent protection for this drug. Since 2007, Sanofi has provided more than 400 million treatments.</p> <p>In addition, we continue our R&D investment to discover new and innovative treatments. We also contribute to raise awareness among communities (especially through our “Schoolchildren Against Malaria” program), we help build capacities (e.g. pharmacovigilance systems) and train healthcare professionals.</p>
<p>Partners: Drugs for Neglected Disease <i>initiative</i></p>
<p>Links/sources: http://en.sanofi.com/csr/patient/priorities/access_to_care/access_to_medicines/malaria/malaria.aspx</p>
<p>Other SDG Goals addressed: SDG Goal 1 – No Poverty</p>

Fighting neglected tropical diseases

Since 2001, Sanofi has been actively engaged in the fight against neglected tropical diseases in partnership with the World Health Organization. Our aim is to combine our efforts with those of national programs, research bodies, NGOs and all involved to provide the poorest communities with a means to be treated. Over the period 2001-2016, Sanofi contributed US\$75 million in financial support and drug donations. In the field of Human African Trypanosomiasis (HAT), or sleeping sickness, thanks to the WHO-Sanofi partnership, the number of cases has dropped drastically and the number of cases identified in 2015 was only 2,804. Since 2001, more than 200,000 patients have received treatment for this disease, which is fatal if left untreated. Moreover, over the same period, more than 36 million people have been screened. Sanofi, in partnership with Drugs for Neglected Diseases *initiative* (DNDi) Foundation is developing a new oral treatment. These initiatives aim to eliminate sleeping sickness as a public health problem by 2020. Sanofi is also a signatory of the 2012 London Declaration on Neglected Tropical Diseases.

Partners: World Health Organization, Drugs For Neglected Diseases *initiative*

Links/sources:

http://en.sanofi.com/csr/patient/priorities/access_to_care/access_to_medicines/neglected_tropical_diseases/neglected_tropical_diseases.aspx

Other SDG Goals addressed: SDG Goal 1 – No Poverty

Dengue Patrol Program

In Malaysia, the Dengue Patrol Program is a school-based program developed in cooperation with the Ministry of Education and the Ministry of Health designed to help Malaysians combat dengue through existing education channels. Started in 2011 as a pilot program and turning nationwide in 2014, it aims to educate and empower young children to be ambassadors of dengue prevention.

It is executed in 3 phases:

1. Students are given dengue talks, which give them with the right basics on dengue prevention.
2. Dengue Patrollers are empowered to initiate their own dengue prevention activities. The Dengue Patrol teams roll out activities such as health talks, home inspection, anti-Dengue bulletin board in school, Search and Destroy activities, Dengue/Aedes exhibition, Hospital Visits to disseminate information as well as creating online buzz through social media.
3. Finally, each team submits its work to a jury (representatives from Sanofi Pasteur, Ministry of Health and Ministry of Education). Selected winning projects are based on originality and execution.

To date, the program has involved more than 250 schools, representing more than 12,500 students across Malaysia. In 2016, the Dengue Patrol Program received the Corporate Social Responsibility award at the Malaysian French Chamber of Commerce and Industry 26th Gala Diner. It was also recognized by the in-house Sanofi CSR Awards.

This program is one example among many demonstrating Sanofi's commitment and comprehensive approach to fight dengue beyond the development and marketing of a new vaccine.

Partners: Ministries of Education and Health of Malaysia

Links/sources: - <https://www.youtube.com/watch?v=22F-wOJ8ia0>

Other SDG Goals addressed: -

Polio price mechanism for the world's poorest countries

In 2014, Sanofi Pasteur, the vaccine division of Sanofi, and the Bill & Melinda Gates Foundation announced a joint price support mechanism, including financial contributions from both organizations, to achieve the goal of polio eradication by 2018. The mechanism allows Sanofi Pasteur to offer Inactivated Poliovirus Vaccine (IPV) to 73 of the world's poorest countries. This is in line with the WHO's recommendation that by end of 2015, all children receive routinely at least one dose of IPV in over 120 countries that solely use oral polio vaccine. This initiative was recognized as one of the 35 business commitments agreed upon during the United Nations Private Sector Forum 2015 in order to achieve the new SDGs.

Partners: Bill & Melinda Gates Foundation, GAVI

Links/sources: <http://www.sanofipasteur.com/en/articles/inactivated-polio-vaccines-broadly-available-for-the-world-s-children-in-the-drive-toward-polio-eradication.aspx>

Other SDG Goals addressed: SDG Goal 1 – No Poverty

My Child Matters: Fighting childhood cancer

The Sanofi Espoir Foundation has been running the "My Child Matters" program for more than 10 years. The program aims to help resource-poor countries in Africa, Asia and Latin America to better manage these diseases and give children a better chance of survival. In rich countries, 80% of children with cancer can be cured. This figure drops to 20% or even 10% in low-resource countries where we find 80% of the children affected. Deployed since 2006 in partnership with the International Union Against Cancer (UICC), the St. Jude Children's Research Hospital, the International Society of Pediatric Oncology (SIOP) and other organizations, this program combines financial support, input from international experts, and networking knowledge and best practices. Over ten years, 65 projects have been implemented in 40 countries, contributing to the care of around 50,000 children and the training of around 15,000 healthcare professionals. In 2016, 16 projects were ongoing in Asia, Africa and Latin America. This initiative was recognized as one of the 35 business commitments agreed upon during the United Nations Private Sector Forum 2015 in order to achieve the new SDGs and is also a Sanofi initiative included in the Access Accelerated initiatives, a cooperative initiative with 21 other pharmaceutical companies, the World Bank and UICC to contribute to the SDG goals in the field of non-communicable diseases.

Partners: The International Union Against Cancer (UICC), the St. Jude Children's Research Hospital, the International Society of Pediatric Oncology (SIOP) and other organizations

Links/sources:
http://fondation-sanofi-espoir.com/en/fighting_against_childhood_cancer.php
<http://www.accessaccelerated.org/initiative/my-child-matters/>

Other SDG Goals addressed: SDG Goal 4 – Quality Education

TB Drug Accelerator
In August 2012 Sanofi, together with six other pharmaceutical companies, eight research institutions, and the Bill & Melinda Gates Foundation, launched a groundbreaking partnership that aims to speed up the discovery of essential new treatments for tuberculosis (TB). The partnership, known as the TB Drug Accelerator (TBDA), will target the discovery of new TB drugs by collaborating on early-stage research. The long-term goal of the TBDA is to create a TB drug regimen that cures patients in only one month. The existing drugs, all at least 50 years old, require six months to cure the disease—a length of time that itself contributes to 20 to 30% of patients dropping out before completion. Aided by nearly US\$20 million (approximately €16.5 million) from the Gates Foundation, the partners officially launched the TBDA in April 2012 and have begun the first round of screening for new TB drug candidates. The TBDA aims to develop five new pre-clinical drug candidates with treatment-shortening potential within five years, and proof-of-concept for a one-month, three-drug regimen within ten years.
Partners: Other pharmaceutical companies, Bill & Melinda Gates Foundation, research institutions
Links/sources: http://partnerships.ifpma.org/partnership/tb-drug-accelerator-program
Other SDG Goals addressed: SDG Goal 1 – No Poverty

SDG GOAL 4 – QUALITY EDUCATION

Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all



e-diabete
Sanofi is a partner of the e-diabete project. The e-diabete health professional training program is managed with the Université numérique francophone mondiale (UNFM), Senghor University and the Réseau en Afrique francophone pour la télémédecine (RAFT). In 2016, it was available in 13 African countries through the use of low-speed internet. Each month, around 1,000 participants may attend an interactive session presented by local and international experts. Participation in the teleconferences is increasingly expanded to include not only diabetologists but also internists, nurses, cardiologists, surgeons and other healthcare professionals. The goal is to have all healthcare professionals aligned when providing primary care to diabetic patients, in order to improve early diagnosis and reduce the risk of related complications and premature deaths. In 2016, there were also 48,500 connections on the e-diabete website to consult training materials.
Partners: The Université numérique francophone mondiale (UNFM), Senghor University and the Réseau en Afrique francophone pour la télémédecine (RAFT)
Links/sources: Brochure Sanofi and Africa “A Sustained Commitment to Serving Patients,” accessible from: http://en.sanofi.com/csr/download_center/download_center.aspx
Other SDG Goals addressed: SDG Goal 8 – Decent work and economic growth

SDG GOAL 5 – GENDER EQUALITY

Achieve gender equality and empower all women and girls



Reducing maternal and neonatal mortality
The Sanofi Espoir Foundation commits to help reducing the maternal and neonatal mortality by creating the Midwives for Life initiative with its main partner, the International Confederation of Midwives (ICM), and many other key international NGOs and local partners. This international partnership aims to better address the challenge of women empowerment and delivery in safer conditions with holistic approaches to health and development. At the end of 2016, 10 long-term programs were underway to reduce maternal and neonatal mortality. In 2014, the Sanofi Espoir Foundation launched the Midwives for Life Awards to reward initiatives carried out by midwives with the aim of reducing maternal and newborn mortality and improving the health of women and newborns in developing countries. In 2016, eight projects (from Afghanistan, Comoros, Indonesia, Côte d'Ivoire, the Gambia, Malawi, Zambia and Chile/Ecuador) were selected by a jury of experts.
Partners: International Confederation of Midwives, international NGOs and local partners
Links/sources: http://fondation-sanofi-espoir.com/en/fighting_against_maternal_neonatal_mortality.php
Other SDG Goals addressed: SDG Goal 3 – Good Health and well-being

SDG GOAL 6 – CLEAN WATER AND SANITATION

Ensure availability and sustainable management of water and sanitation for all



Peres Center for Peace
Water quality is especially important in areas where water is a precious, limited resource. For several years, Sanofi has supported an Israeli-Palestinian research program run by the Peres Center for Peace, an NGO in Jaffa that brings together Israeli and Palestinian researchers and graduate students from the Technion Institute of Technology in Haifa and Al-Quds University near Jerusalem. The program evaluates different biological treatments, absorption and membrane techniques to determine their effectiveness in removing APIs from wastewater, whether domestic or industrial. In 2014, results from the research program were written up in co-authored scientific publications. These efforts may contribute to improving the quality of drinking and irrigation water across the Middle East, an area of high water stress.
Partners: Peres Center for Peace
Links/sources: -
Other SDG Goals addressed: -

SDG GOAL 7 – AFFORDABLE AND CLEAN ENERGY

Ensure access to affordable, reliable, sustainable and modern energy for all



Decreasing our carbon footprint
<p>Sanofi has taken the initiative to achieve a 20% reduction in the combined scope 1 and scope 2 CO₂ emissions for industrial and R&D sites and sales force vehicles. To reach this goal, Sanofi has formed strategic partnerships with energy sector leaders, implemented renewable energy projects at our sites in India, and continued our vehicle policy, including the increase in eco-driving sessions. From 2010 to 2014, the fuel consumption by medical sales teams decreased by 22.3%. Sanofi also gives priority to shipping medicines by rail and water. In 2014, Sanofi made 86% of its intercontinental shipments by sea compared to an average of 28% for other health companies. Maritime transport emits 30 times less CO₂ than air transport, which represents 260,000 tons of CO₂ saved per year by Sanofi thanks to shipping by sea.</p>
<p>Partners: -</p>
<p>Links/sources: -</p>
<p>Other SDG Goals addressed: -</p>

SDG GOAL 9 – INDUSTRY, INNOVATION AND INFRASTRUCTURE

Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation



Improving supply chain management in Morocco
<p>Sanofi Morocco designed together with the Ministries of Health and Industry an agreement that aims at sharing the expertise of Sanofi in supply chain management. This partnership aimed at training technicians, engineers and staff from the Minister of Health to the jobs of the pharmaceutical industry, including good distribution practices, hygiene, safety and environment, and logistics and distribution. This partnership met the needs identified in Morocco in terms of poor estimation of drug needs by public hospitals, absence of a hospital information system, unsuitable storage of local products, gaps in the inventory management and lack of means for the destruction of expired drugs. By the end of 2014, more than 700 people had been trained.</p>
<p>Partners: Ministry of Health of Morocco, Ministry of Industry of Morocco</p>
<p>Links/sources: http://en.sanofi.com/Images/32582_20130417_MAROC_en.pdf</p>
<p>Other SDG Goals addressed: SDG Goal 10 – Reduce inequalities</p>

SDG GOAL 10 – REDUCED INEQUALITIES

Reduce inequalities within and among communities



Malaria: Data sharing collaboration with the WWARN
In January 2012 Sanofi entered into a collaboration with the WorldWide Antimalarial Resistance Network (WWARN), to aid in its attempt to detect and fight resistance to current anti-malarial drugs around the world. Through this agreement, Sanofi will contribute to provide data to WWARN's central database of information relating to anti-malarial drug resistance, for medication developed by Sanofi and the Drugs for Neglected Diseases <i>initiative</i> (DNDi)—thereby underlining our commitment to the global fight against malaria. Although mortality rates due to malaria have fallen by more than 25% since 2000, these gains are now threatened by emerging resistance to the globally-recommended artemisinin-combination therapies in Southeast Asia. It is therefore crucial that all stakeholders join forces to monitor and fight the spread of resistance to life-saving drugs, and invest in the search for new medicines.
Partners: WorldWide Antimalarial Resistance Network
Links/sources: http://www.wwarn.org/news/press-releases/wwarn-and-sanofi-agree-data-sharing-collaboration
Other SDG Goals addressed: SDG Goal 3 – Good Health and well-being

SDG GOAL 12 – RESPONSIBLE CONSUMPTION AND PRODUCTION

Ensure sustainable consumption and production patterns



Take-back programs
To protect local ecosystems, Sanofi has been supporting take-back programs that collect unused and expired medicines from patients and inform consumers about their safe disposal. Sanofi has supported such programs in 15 countries, including Brazil, Colombia, Mexico, The Philippines, Saudi Arabia, Venezuela, etc. In Colombia, the “Punto Azul” (Blue Point) program has set up collection points for unused medicines across 23 Colombian states, representing 47.9% of the country’s population. This program, which is funded by manufacturers and importers of medicines, was created by the National Association of Colombian Enterprises (ANDI) in 2010.
Partners:
Links/sources:
Other SDG Goals addressed: SDG Goal 15 – Life on land

SDG GOAL 13 – CLIMATE ACTION



Take urgent action to combat climate change and its impacts

Addressing the impact of climate change on health
<p>Sanofi is committed to addressing climate change in order to raise awareness about the consequences of climate change on health among our stakeholders. In 2015, we set up an advisory board with external experts in the fields of climate and health in order to better understand the issues at stake and define the approach to adopt. Our commitment took several forms. Sanofi was an official partner of COP 21 in Paris in December 2015. On this occasion, our CEO signed the French business climate pledge with 38 other French companies to combat climate change. In 2016, as an extension of our commitment, Sanofi participated to COP 22 and the Head of CSR took part in several conferences in Marrakech. Our Moroccan affiliate was also represented and showcased Sanofi's activities aimed at controlling our environmental footprint. It also presented our strategy to anticipate the consequences of climate change on health – for instance, with regards to the allergies caused by pollution, vector-borne diseases (e.g., dengue, malaria, etc.), diabetes and cardiovascular diseases.</p> <p>For more information, see the factsheet “Sanofi’s Risks Related to Climate Change and Health Opportunities” in our Download Center: http://en.sanofi.com/csr/download_center/download_center.aspx</p>
Partners: -
Links/sources: <p>French Business Climate Pledge (in French) http://www.cop21.gouv.fr/wp-content/uploads/2015/11/French-Business-Climat-Pledge-FR-FINAL.pdf Our commitment towards mitigation: https://www.youtube.com/watch?v=xuWOseEoy5U Transport of medicine and environmental preservation : https://www.youtube.com/watch?v=egp0ir5wxVE Our solutions to tackle health issues related to climate change: https://www.youtube.com/watch?v=Ru02lwQx4gU Sanofi's research on infectious diseases and their evolution due to climate change: https://www.youtube.com/watch?v=OYPADQBpVQY English version of O. Brandicourt's op-ed: http://www.huffingtonpost.com/olivier-brandicourt/health-the-glar-ing-omissi_1_b_8707444.html Sanofi at COP 22: http://en.sanofi.com/csr/news/2016-11-07-COP22-sanofi-extends-its-commitment.aspx and https://lehub.sanofi.com/en/prevention-support/cop22-sanofi-maroc/</p>
Other SDG Goals addressed: SDG Goal 3 – Good Health and well-being; SDG Goal 5 – Affordable and clean energy

Fighting dengue, a climate-sensitive disease

Climate change may extend the transmission season and alter the geographical distribution of dengue, particularly due to weather variations (increased temperatures or tropical rains). This could lead to: i/ increased number of mosquitoes as environmental conditions become more favorable; ii/ the expansion of the vectors and virus to previously unaffected areas; iii/ shorter incubation of the virus in the vector, leading to more explosive outbreak; iv/ changes in vector biology and biting habits, facilitating increased transmission, and v/ changes in human behavior, in response to climate change, that place them at elevated risks of dengue. After 20 years of research and development, Sanofi Pasteur launched the first dengue vaccine. On December 9, 2015, Mexico was the first country to grant marketing authorization to Dengvaxia®, our tetravalent vaccine for the prevention of diseases caused by all four dengue virus serotypes in preadolescents, adolescents, and adults (aged 9 to 45) living in endemic areas. The marketing authorization of Dengvaxia® in Mexico was followed by approvals in the Philippines and Brazil in 2015 and El Salvador in 2016. As of December 1, 2016, Dengvaxia® had been approved in 13 countries (Bolivia, Brazil, Cambodia, Costa Rica, Guatemala, El Salvador, Indonesia, Mexico, Paraguay, Peru, the Philippines, Singapore, Thailand). Public programs are underway in Brazil (for children, adolescents and adults in Parana State) and the Philippines (through a school-based program). Sanofi has invested €1.5 billion in dengue vaccine R&D and production including €350 million in state-of-the-art vaccine production facilities. At full capacities, the plant in Neuville-sur-Saône (France) is set to produce around 100 million doses per year as soon as 2016. We are introducing Dengvaxia® first in those countries where the vaccine has the greatest potential to reduce dengue burden globally and help achieve the WHO's goal of reducing dengue mortality by 50 percent and morbidity by 25 percent by 2020 in endemic countries. Regulatory review processes for Dengvaxia® continue in other endemic countries, and Sanofi Pasteur remains committed to introducing the vaccine first in countries where the disease is a major public health priority. In July 2016, the WHO issued its recommendation that countries with a high dengue burden consider vaccination to help better control the disease.⁴

Partners: -


Links/sources:

Sanofi committed against dengue fever, a disease impacted by climate change :
<https://www.youtube.com/watch?v=1j7FUmkDr5Q>
<http://www.sanofipasteur.com/en/articles/dengvaxia-world-s-first-dengue-vaccine-approved-in-mexico.aspx>
<http://www.sanofipasteur.com/en/articles/sanofi-pasteur-dengue-vaccine-approved-in-the-philippines.aspx>
<http://www.sanofipasteur.com/en/articles/Dengvaxia-First-Dengue-Vaccine-Approved-in-Brazil.aspx>
http://www.sanofipasteur.com/en/Documents/PDF/PR-locaux/El%20Salvadore%20LICENSE%20DENGVAXIA%20ENG_050216.pdf
<http://www.sanofipasteur.com/en/articles/World-s-First-Public-Dengue-Immunization-Program-Starts-in-the-Philippines.aspx>

Other SDG Goals addressed: SDG Goal 2 – Zero hunger; SDG Goal 3 – Good Health and well-being

⁴ WHO, Weekly Epidemiological Record, No 30, July 2016, 91, pp. 349 – 364: <http://www.who.int/wer/2016/wer9130.pdf?ua=1>

SDG GOAL 16 – PEACE, JUSTICE AND STRONG INSTITUTIONS



Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable and inclusive institutions at all levels

Supporting the refugees
<p>Due to the increasing violence and intensification of conflicts in the Middle East, the number of refugees from Syria, Iraq and Yemen continues to grow. In 2015, as part of its humanitarian emergencies response program, the Sanofi Espoir Foundation provided financial aid to its partners on the ground in Iraq, Yemen and the gates of Europe (Macedonia, Greece, Turkey and Serbia) amounting to €110,000. The Foundation supports Première Urgence Internationale (PUI) at the camp located in the Bardarash district, Iraq, home to nearly 10,000 people, to implement medical support, provide primary care and promote good health practices. In 2016, the Sanofi Espoir Foundation supported a project led by PUI to improve the health of women and children in the Bardarash camp by setting up a special facility exclusively for women, whether pregnant or not, and their children. This mother-and-child center includes medical services such as immunization for children, psychosocial services and gynecological care. In all, 11,409 people have been helped by the project, which means about 2,200 families. In Yemen, the Foundation contributes to the READY Emergency Fund set up by the French Red Cross to improve living conditions for refugees by providing hygiene kits, shelters and food. In Serbia, Macedonia, Turkey and Greece, the Foundation supports the NGO WAHA in implementing medical support at the arrival points and the refugee camps, including provision of primary, gynecological and pediatric care in partnership with local NGOs. Moreover, since 2015, in light of the urgency of the situation of the migrants in Calais, the Sanofi Espoir Foundation has supported the long-term actions set up by its partners Médecins du Monde and Gynécologie Sans Frontières to help these vulnerable populations in extremely difficult living conditions..</p>
<p>Partners: Première urgence internationale, French Red Cross, WAHA, Médecins du Monde, Gynécologie Sans Frontières</p>
<p>Links/sources: http://fondation-sanofi-espoir.com/en/news-2015-09-22-supporting-the-refugees.php http://fondation-sanofi-espoir.com/en/news-2016-09-12-mother-child-center-bardarash.php http://fondation-sanofi-espoir.com/en/news-2016-06-22-bardarash.php http://fondation-sanofi-espoir.com/actus-2016-04-29-soutien-aux-migrants.php</p>
<p>Other SDG Goals addressed: -</p>

Human Rights in our activities
<p>Sanofi is committed to integrating respect for Human Rights into all our business operations and public positions. For several years, Sanofi has expressed and reiterated our commitment to the ten principles of the United Nations Global Compact and other international standards in the field of Human Rights. We are committed to promoting respect for Human Rights principles in all areas of our business—from improving access to healthcare and upholding ethical standards to respecting fundamental employee rights and taking steps to preserve our planet. Sanofi has designed a ‘Human Rights in our Activities’ guide with three aims: inform and familiarize all Sanofi employees with a focus on managers, with the key principles linked to the respect of Human Rights taking into account stakeholders’ expectations; describe a selection of Sanofi good practices at every step of drugs’ life cycle and in the workplace; act as a reference point for all Sanofi’s managers making decisions about potential issues linked to Human Rights in their daily activity.</p>
<p>Partners: -</p>
<p>Links/sources: http://csr-humanrights.sanofi.com/sanofi_comitment.html</p>
<p>Other SDG Goals addressed:</p>

SDG GOAL 17 – PARTNERSHIPS FOR THE GOALS



Strengthen the means of implementation and revitalize the global partnership for sustainable development

Access Accelerated Initiative
<p>In January 2017, during the World Economic Forum in Davos, Switzerland, Sanofi together with 21 of our industry competitors and peers, the World Bank and the Union for International Cancer Control (UICC) launched the Access Accelerated Initiative (AAI), a new coalition to address the burden of non-communicable diseases (NCDs) in low- and lower-middle income countries. Through the launch of the AAI, companies are committing their resources and expertise towards achieving one of the UN Sustainable Development Goals: to reduce premature deaths from NCDs by one-third by 2030. Under the Access Accelerated coalition, Sanofi will work together with 21 industry partners, the World Bank and the UICC to start with, to:</p> <ul style="list-style-type: none"> • Share best practice gathered from our longstanding commitments and own projects • Design and set up targeted pilot projects, with the objective of scaling up these projects over time • Identify what is working and what is not, so that we can collectively improve on our efforts to overcome barriers to primary care delivery for NCD patients • Nurture disease-specific partnerships, starting with the development of effective, sustainable cancer care delivery models in a number of pilot cities <p>Sanofi's AAI commitment includes four flagship programs developed with specific partners:</p> <ul style="list-style-type: none"> • FAST – Fight Against Stigma, in the field of mental health • My Child Matters, in the field of childhood cancer • KiDS and diabetes in Schools • Access and Affordability initiative, testing the impact of differential pricing for NCD treatments in Ghana and the Philippines. <p>Our efforts will be evaluated with the support of independent experts at Boston University to establish a framework for progress, measure effectiveness and deliver ongoing reporting. This means that we will be able to review and assess our impact on a regular basis, making any necessary adjustments and providing a solid platform for engagement at local and national level.</p>
<p>Partners: 21 other pharma companies, World Bank, UICC</p>
<p>Links/sources: Official website of Access Accelerated: http://www.accessaccelerated.org/ Sanofi's commitment: https://lehub.sanofi.com/en/access-healthcare/access-accelerated-initiative/</p>
<p>Other SDG Goals addressed: SDG Goal 3 – Good Health and Well-Being</p>

BSR's Guiding Principles on Access to Healthcare
<p>Sanofi is a signatory of BSR's Guiding Principles on Access to Healthcare. This sector-wide initiative aims to help frame and describe the healthcare industry's approach to reducing the global burden of disease and improving global health outcomes. As a set of industry-wide principles and approaches, the Guiding Principles on Access to Healthcare recognize the importance of five core areas: collaboration, research & development, expanding availability of healthcare services, developing health systems resources, respecting Human Rights. These Guiding Principles on Access to Healthcare have been signed by the CEOs of 13 major healthcare companies with global partnerships in pharmaceuticals, vaccines, diagnostics and other medical technology.</p>
<p>Partners: BSR, other healthcare companies</p>
<p>Links/sources: http://gpah.bsr.org/</p>
<p>Other SDG Goals addressed: -</p>